Uptravi
EMA green lights Actelion’s drug after patient deaths scare
April 10, 2017Sales and Marketing Actelion, Johnson & Johnson, Uptravi
The EMA has ruled that the five patient deaths that occurred in February of this year were not directly related …
Actelion granted EU approval for hypertension treatment
May 17, 2016Manufacturing and Production, Sales and Marketing Actelion, Uptravi, eu approval, hypertension
Actelion Pharmaceuticals has received marketing authorisation from the European Commission for Uptravi (selexipag) for the long-term treatment of patients with …
Actelion’s Uptravi and rare bleeding disorder drug get positive EMA decisions
February 1, 2016Sales and Marketing CHMP, EMA, Uptravi, pulmonary arterial hypertension, selexipag
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has issued positive opinions on …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
Actelion ready to launch Uptravi after FDA approval
December 22, 2015Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag
Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …
